Citigroup
MNPR icon

Citigroup’s Monopar Therapeutics MNPR Stock Holding History

Citigroup’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.7K Sell
232
-13,608
-98% -$822K ﹤0.01% 4957
2025
Q4 		$904K Buy
13,840
+13,689
+9,066% +$1.12M ﹤0.01% 3203
2025
Q3 		$12.3K Sell
151
-1,292
-90% -$57.8K ﹤0.01% 4955
2025
Q2 		$51.6K Buy
1,443
+1,218
+541% +$44.2K ﹤0.01% 4738
2025
Q1 		$8.19K Buy
+225
New +$8.11K ﹤0.01% 5220

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's MNPR Position: Q1 2026 in Review

Citigroup reduced its Monopar Therapeutics (MNPR) stake by 98% in Q1 2026, selling an estimated $822K and leaving 232 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4957.

Citigroup first reported a position in MNPR in Q1 2025 and has held it in 5 quarters since. The position peaked at $904K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Citigroup held 232 shares of Monopar Therapeutics worth $12.7K as of Q1 2026.
  • Citigroup sold 13,608 Monopar Therapeutics shares in Q1 2026, an estimated $822K.
  • Monopar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4957 holding.
  • Citigroup first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Citigroup's Monopar Therapeutics position peaked at $904K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.